Results 11 to 20 of about 123,913 (326)

Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA. [PDF]

PLoS ONE, 2012
Dopamine D(2) receptor partial agonist antipsychotic drugs can modulate dopaminergic neurotransmission as functional agonists or functional antagonists.
Hiroshi Ito, Harumasa Takano, Ryosuke Arakawa, Hidehiko Takahashi, Fumitoshi Kodaka, Keisuke Takahata, Tsuyoshi Nogami, Masayuki Suzuki, Tetsuya Suhara   +8 more
doaj   +1 more source

Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report

Journal of Medical Case Reports, 2019
Background Dopamine agonists are the standard first-line medical therapy for prolactinoma. We report a rare case of giant prolactinoma with a first epileptic seizure due to rapid reduction of the tumor as a complication of dopamine agonist therapy.
Motofumi Koguchi, Yukiko Nakahara, Ryo Ebashi, Atsushi Ogata, Shoko Shimokawa, Jun Masuoka, Tatsuya Abe   +6 more
doaj   +1 more source

D1 receptor agonist improves sleep–wake parameters in experimental parkinsonism

Neurobiology of Disease, 2014
Both excessive daytime sleepiness (EDS) and rapid eye movement (REM) sleep deregulation are part of Parkinson's disease (PD) non-motor symptoms and may complicate dopamine replacement therapy.
Carole Hyacinthe, Quentin Barraud, François Tison, Erwan Bezard, Imad Ghorayeb   +4 more
doaj   +1 more source

Dopaminergic activation of estrogen receptors induces fos expression within restricted regions of the neonatal female rat brain. [PDF]

PLoS ONE, 2008
Steroid receptor activation in the developing brain influences a variety of cellular processes that endure into adulthood, altering both behavior and physiology.
Kristin M Olesen, Anthony P Auger
doaj   +1 more source

Dopamine genetic risk score predicts impulse control behaviors in Parkinson’s disease

Clinical Parkinsonism & Related Disorders, 2021
Introduction: Up to 40% of Parkinson’s disease patients taking dopamine agonist medication develop impulse control behaviors which can have severe negative consequences.
Alison Hall, Samuel R. Weaver, Lindsey J. Compton, Winston D. Byblow, Ned Jenkinson, Hayley J. MacDonald   +5 more
doaj   +1 more source

Orexin-Corticotropin-Releasing Factor Receptor Heteromers in the Ventral Tegmental Area as Targets for Cocaine [PDF]

, 2015
Release of the neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the ventral tegmental area (VTA) play an important role in stress-induced cocaine-seeking behavior.
Aguinaga, David, Cai, Ning-Sheng, Canela, Enric I, Casadó, Vicent, Cortés, Antonio, Ferré, Sergi, Hausch, Felix, Howell, Lesley A., Lluís, Carme, Mallol, Josefa, McCormick, Peter J., McDowell, Kimberly, Moreno, Estefanía, Moreno-Delgado, David, Navarro, Gemma, Quiroz, César, Rea, William, Sierakowiak, Adam   +17 more
core   +1 more source

Infusion of D1 dopamine receptor agonist into medial frontal cortex disrupts neural correlates of interval timing

Frontiers in Behavioral Neuroscience, 2015
Medial frontal cortical (MFC) dopamine is essential for the organization of behavior in time. Our prior work indicates that blocking D1 dopamine receptors (D1DR) attenuates temporal processing and low-frequency oscillations by MFC neuronal networks ...
Krystal L Parker, Rafael N Ruggiero, Nandkumar S Narayanan   +2 more
doaj   +1 more source

A Role for Adenosine A1 Receptors in GABA and NMDA-Receptor Mediated Modulation of Dopamine Release: Studies Using Fast Cyclic Voltammetry

Sensors, 2008
In the striatum many neurotransmitters including GABA, glutamate, acetylcholine, dopamine, nitric oxide and adenosine interact to regulate synaptic transmission. Dopamine release in the striatum is regulated by a number of pre- and postsynaptic receptors
Carmel O’Neill, John J. O’Connor   +1 more
doaj   +1 more source

Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment [PDF]

, 1997
Neuropsychiatric side effects often complicate anti-Parkinsonian therapy and pose a significant problem in the optimal management of idiopathic Parkinson's disease.
Abbott, R.J., Chaudhuri, K.R., Ellis, C, Leigh, P.N., Lemmens, Gilbert, Parkes, J.D., Pye, I.F.   +6 more
core   +2 more sources

Clinical guidelines ‘Hyperprolactinemia’ (draft)

Ожирение и метаболизм, 2023
Hyperprolactinemia is a persistent excess of the blood serum prolactin. The syndrome contains various symptoms, the most characteristic is a violation of the reproductive system.
I. I. Dedov, G. A. Melnichenko, L. K. Dzeranova, E. N. Andreeva, E. N. Grineva, E. I. Marova, N. G. Mokrysheva, E. A. Pigarova, S. Y. Vorotnikova, N. S.  Fedorova, A. S. Shutova, E. G. Przhiyalkovskaya, I.  A.  Ilovaуskaya, T. I. Romantsova, S. A. Dogadin, L. A. Suplotova   +15 more
doaj   +1 more source